{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T09:10:43Z","timestamp":1775466643685,"version":"3.50.1"},"reference-count":219,"publisher":"Wiley","issue":"s70","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with von Willebrand disease (VWD) and haemophilia A (HA) lack, to varying degrees, the von Willebrand factor (VWF) and coagulation factor VIII (FVIII) that are critical for normal haemostasis. These conditions in turn make patients prone to uncontrolled bleeding. Historically, patients with severe forms of VWD or HA were crippled before adulthood and their life expectancy was significantly reduced. Over the past decades, specific coagulation factor replacement therapies including Haemate<jats:sup>\u00ae<\/jats:sup>P, have been developed to help patients achieve and maintain normal haemostasis. Haemate<jats:sup>\u00ae<\/jats:sup>P is a human, plasma\u2010derived VWF\/FVIII medicinal product, which was first licensed in Germany in 1981 for the treatment of HA\u2010associated bleeding. It has since then come to be accepted as the gold standard for both the treatment and prophylaxis of bleeding in VWD, especially in cases where desmopressin [1\u2010deamino\u20108\u2010<jats:sc>D<\/jats:sc>\u2010arginine vasopressin (DDAVP)] has been ineffective. Haemate<jats:sup>\u00ae<\/jats:sup>P was the first effectively virus\u2010inactivated (pasteurisation: 60\u00b0C for 10\u2003h in aqueous solution) FVIII product, whereby the risk of potentially threatening infective complications of plasma\u2010derived products was reduced. Haemate<jats:sup>\u00ae<\/jats:sup>P was also shown to have a VWF multimer profile remarkably close to that of normal plasma. This bibliographic review presents previously unpublished clinical data of Haemate<jats:sup>\u00ae<\/jats:sup>P, based upon internal clinical study reports of the proprietor, CSL Behring, in addition to data already presented in other publications. The data demonstrate a predictable and well\u2010characterised pharmacokinetic profile, and a proven record of short\u2010 and long\u2010term safety, while effectively correcting the haemostatic defects in VWD and HA. Recently available data have also shown Haemate<jats:sup>\u00ae<\/jats:sup>P to be of haemostatic value in exceptional clinical circumstances including surgical interventions. By virtue of its plasma\u2010derived combination of VWF and FVIII, in addition to its high VWF:FVIII content ratio (2.4:1), Haemate<jats:sup>\u00ae<\/jats:sup>P is also associated with successful immune tolerance induction in those patients developing inhibitor antibodies. Although the theoretical risk of thromboembolic complications does exist while receiving Haemate<jats:sup>\u00ae<\/jats:sup>P, as it does with any FVIII replacement therapy, the incidence of such complications has remained notably low. Given the robust data that have accumulated for the use of Haemate<jats:sup>\u00ae<\/jats:sup>P, dosing recommendations are also described in this review; the recommendations are tailored to patient\u2010specific contexts including baseline VWF and FVIII levels in plasma and the type of surgical intervention being undertaken. A wide variety of studies have also provided data on paediatric and geriatric populations, all of which have suggested that Haemate<jats:sup>\u00ae<\/jats:sup>P can be safely and effectively used in a wide variety of clinical circumstances.<\/jats:p>","DOI":"10.1111\/j.1600-0609.2008.01049.x","type":"journal-article","created":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T16:46:44Z","timestamp":1207068404000},"page":"3-35","source":"Crossref","is-referenced-by-count":38,"title":["A systematic overview of the first pasteurised VWF\/FVIII medicinal product, Haemate<sup>\u00ae<\/sup>P\/\u200aHumate<sup>\u00ae<\/sup>\u2010P: History and clinical performance"],"prefix":"10.1111","volume":"80","author":[{"given":"Erik","family":"Berntorp","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Archey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G\u00fcnter","family":"Auerswald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Augusto B.","family":"Federici","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Franchini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sigurd","family":"Knaub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wolfhart","family":"Kreuz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Lethagen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pier M.","family":"Mannucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hartmut","family":"Pollmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Scharrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keith","family":"Hoots","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,4]]},"reference":[{"key":"e_1_2_10_2_2","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1182\/blood.V79.10.2507.bloodjournal79102507","article-title":"Molecular genetics of von Willebrand disease","volume":"79","author":"Ginsburg D","year":"1992","journal-title":"Blood"},{"key":"e_1_2_10_3_2","first-page":"147","volume-title":"Factor VIII \u2013 von Willebrand Factor","author":"Goodall AH","year":"1989"},{"key":"e_1_2_10_4_2","first-page":"1409","volume-title":"Williams Hematology","author":"Roberts HR","year":"2001"},{"key":"e_1_2_10_5_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V57.6.1140.1140"},{"key":"e_1_2_10_6_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V70.4.895.895"},{"key":"e_1_2_10_7_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1648506"},{"key":"e_1_2_10_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0609190103"},{"key":"e_1_2_10_9_2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V63.1.128.128","article-title":"Adhesion of platelets to human artery subendothelium: effect of factor VIII\u2010von Willebrand factor of various multimeric composition","volume":"63","author":"Sixma JJ","year":"1984","journal-title":"Blood"},{"key":"e_1_2_10_10_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V67.2.322.322"},{"key":"e_1_2_10_11_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1646168"},{"key":"e_1_2_10_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1991.tb43698.x"},{"key":"e_1_2_10_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1987.tb13480.x"},{"key":"e_1_2_10_14_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1987.tb13331.x"},{"key":"e_1_2_10_15_2","first-page":"233","article-title":"Molecular and cellular biology of von Willebrand factor","volume":"9","author":"Handin RI","year":"1989","journal-title":"Prog Hemost Thromb"},{"key":"e_1_2_10_16_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V58.1.1.1"},{"key":"e_1_2_10_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199401063300108"},{"key":"e_1_2_10_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01703248"},{"key":"e_1_2_10_19_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI113721"},{"key":"e_1_2_10_20_2","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1055\/s-0038-1646161","article-title":"Factor VIII structure and function","volume":"70","author":"Fay PJ","year":"1993","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_21_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-4571"},{"key":"e_1_2_10_22_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00350a035"},{"key":"e_1_2_10_23_2","doi-asserted-by":"publisher","DOI":"10.1021\/bi00337a007"},{"key":"e_1_2_10_24_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1432-1033.1990.tb15481.x"},{"key":"e_1_2_10_25_2","first-page":"94","article-title":"Von Willebrand\u2019s disease in the year 2003: towards the complete identification of gene defects for correct diagnosis and treatment","volume":"88","author":"Castaman G","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_10_26_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V69.2.454.454"},{"key":"e_1_2_10_27_2","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2000.1.241"},{"key":"e_1_2_10_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01402.x"},{"key":"e_1_2_10_29_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1992.tb00584.x"},{"key":"e_1_2_10_30_2","volume-title":"Von Willebrand Disease: An Introductory Discussion for Young Physicians","author":"Kasper CK"},{"key":"e_1_2_10_31_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V92.8.2707"},{"key":"e_1_2_10_32_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1614018"},{"key":"e_1_2_10_33_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2005.11.003"},{"key":"e_1_2_10_34_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20830"},{"key":"e_1_2_10_35_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-949663"},{"key":"e_1_2_10_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022831"},{"key":"e_1_2_10_37_2","first-page":"129","volume-title":"Factor VIII \u2013 von Willebrand Factor","author":"Dalton RG","year":"1989"},{"key":"e_1_2_10_38_2","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1055\/s-0038-1657654","article-title":"Plasma derived von Willebrand factor preparations: collagen binding and ristocetin cofactor activities","volume":"78","author":"Chang P","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_39_2","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1055\/s-0037-1613768","article-title":"Collagen binding assay for von Willebrand Factor (VWF:CBA). Detection of von Willebrands disease (VWD), and discrimination of VWD subtypes, depends on collagen source","volume":"83","author":"Favoloro EJ","year":"2000","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_40_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642471"},{"key":"e_1_2_10_41_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1997.tb00175.x"},{"key":"e_1_2_10_42_2","author":"Blood Center of Wisconsin Hemostasis Reference Laboratory","journal-title":"Von Willebrand Disease: Laboratory Evaluation"},{"key":"e_1_2_10_43_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167656.77520.bb"},{"key":"e_1_2_10_44_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-27820"},{"key":"e_1_2_10_45_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.87.16.6306"},{"key":"e_1_2_10_46_2","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood.V88.8.2939.bloodjournal8882939","article-title":"Shear\u2010dependant changes in the three\u2010dimensional structure of human von Willebrand factor","volume":"88","author":"Siediecki CA","year":"1996","journal-title":"Blood"},{"key":"e_1_2_10_47_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V83.8.2171.2171"},{"key":"e_1_2_10_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)91240-4"},{"key":"e_1_2_10_49_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-105-1-54"},{"key":"e_1_2_10_50_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.11.1290"},{"issue":"1","key":"e_1_2_10_51_2","article-title":"Pseudo von Willebrand disease: 2B or not 2B? Cryoprecipitate induced platelet aggregation solves Hamlet\u2019s dilemma","volume":"3","author":"Enayat MS","year":"2005","journal-title":"J Thromb Haemost"},{"key":"e_1_2_10_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0750-7658(89)80185-6"},{"key":"e_1_2_10_53_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-949661"},{"key":"e_1_2_10_54_2","first-page":"169","volume-title":"Hemostasis and Thrombosis \u2013 Basic Principles and Clinical Practice","author":"Brettler DB","year":"1994"},{"key":"e_1_2_10_55_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1615621"},{"key":"e_1_2_10_56_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(87)90235-0"},{"key":"e_1_2_10_57_2","first-page":"33","volume-title":"Factor VIII \u2013 von Willebrand Factor","author":"Beard J","year":"1989"},{"key":"e_1_2_10_58_2","first-page":"134","volume-title":"Hemostasis and Thrombosis \u2013 Basic Principles and Clinical Practice","author":"Montgomery RR","year":"1994"},{"key":"e_1_2_10_59_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167658.85143.49"},{"key":"e_1_2_10_60_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.1058"},{"key":"e_1_2_10_61_2","first-page":"499","article-title":"Diagnosis and treatment of von Willebrand\u2019s disease","volume":"1","author":"Cattaneo M","year":"1994","journal-title":"J Pediatr Hematol Oncol"},{"key":"e_1_2_10_62_2","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1055\/s-0037-1619605","article-title":"Women with von Willebrand disease","volume":"24","author":"Scharrer I","year":"2004","journal-title":"Haemostaseologie"},{"key":"e_1_2_10_63_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-06-2072"},{"key":"e_1_2_10_64_2","first-page":"276","article-title":"Response to 1\u2010deamino\u20108\u2010D\u2010arginine vasopressin in von Willebrand disease","volume":"24","author":"Lusher JM","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_10_65_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91197-7"},{"key":"e_1_2_10_66_2","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood.V72.5.1449.1449","article-title":"Desmopressin: a nontransfusional form of treatment for congenital and acquired bleeding disorders","volume":"72","author":"Mannucci PM","year":"1988","journal-title":"Blood"},{"key":"e_1_2_10_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1992.tb04598.x"},{"key":"e_1_2_10_68_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613992"},{"key":"e_1_2_10_69_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00096.x"},{"key":"e_1_2_10_70_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.0050s2028.x"},{"key":"e_1_2_10_71_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-949667"},{"key":"e_1_2_10_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2006.01.021"},{"key":"e_1_2_10_73_2","first-page":"1648","volume-title":"Hematology: Basic Principles and Practice","author":"Brettler DB","year":"1995"},{"key":"e_1_2_10_74_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2001.00500.x"},{"key":"e_1_2_10_75_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.7.2337"},{"key":"e_1_2_10_76_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa067659"},{"key":"e_1_2_10_77_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.9.s1.17.x"},{"key":"e_1_2_10_78_2","doi-asserted-by":"publisher","DOI":"10.1097\/00003086-199607000-00013"},{"key":"e_1_2_10_79_2","doi-asserted-by":"publisher","DOI":"10.1016\/0030-4220(93)90135-Q"},{"key":"e_1_2_10_80_2","first-page":"174","article-title":"Clinical application of Beriplast P in oral surgery","volume":"11","author":"Yanagiya K","year":"1992","journal-title":"Hayaku Ryohoh 1992"},{"key":"e_1_2_10_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)90874-3"},{"key":"e_1_2_10_82_2","first-page":"57","article-title":"Immune tolerance therapy in pediatric hemophiliacs with Factor VIII Inhibitors","volume":"9","author":"Kreuz W","year":"1996","journal-title":"Biomedical Progress"},{"key":"e_1_2_10_83_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1996.tb01341.x"},{"key":"e_1_2_10_84_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470757260.ch9"},{"issue":"43","key":"e_1_2_10_85_2","first-page":"82","article-title":"Treatment of hemophilia","volume":"43","author":"Meili EO","year":"1991","journal-title":"Schweiz Med Wochenschr"},{"key":"e_1_2_10_86_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00996832"},{"key":"e_1_2_10_87_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1995.tb00036.x"},{"key":"e_1_2_10_88_2","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1055\/s-0038-1655342","article-title":"Epitope specificity of factor VIII inhibitor antibodies","volume":"18","author":"Scandella D","year":"1998","journal-title":"Haemostaseologie"},{"key":"e_1_2_10_89_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2001.00526.x"},{"issue":"9","key":"e_1_2_10_90_2","first-page":"21","article-title":"The role of plasma\u2010derived factor VIII\/von Willebrand factor concentrates in the treatment of hemophilia A patients","volume":"88","author":"Auerswald G","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_10_91_2","first-page":"181","article-title":"Induced immunotolerance in factor VIII inhibitor patients","volume":"150","author":"Brackmann HH","year":"1984","journal-title":"Prog Clin Biol Res"},{"key":"e_1_2_10_92_2","doi-asserted-by":"publisher","DOI":"10.1159\/000056717"},{"key":"e_1_2_10_93_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V86.3.983.983"},{"key":"e_1_2_10_94_2","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/jama.1988.03720010043038","article-title":"Induction of immune tolerance to factor VIII in hemophiliacs with inhibitors","volume":"259","author":"Ewing NP","year":"1988","journal-title":"JAMA"},{"key":"e_1_2_10_95_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.00195.x"},{"issue":"9","key":"e_1_2_10_96_2","first-page":"13","article-title":"Variation in factor VIII inhibitor reactivity with different commercial factor VIII preparations: is it of clinical importance?","volume":"88","author":"Berntorp E","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_10_97_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.mbc.0000167660.30886.e9"},{"key":"e_1_2_10_98_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01373.x"},{"key":"e_1_2_10_99_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1650655"},{"key":"e_1_2_10_100_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00780.x"},{"key":"e_1_2_10_101_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2003.00802.x"},{"key":"e_1_2_10_102_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2006.01400.x"},{"key":"e_1_2_10_103_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-05-022756"},{"key":"e_1_2_10_104_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2001.00473.x"},{"key":"e_1_2_10_105_2","doi-asserted-by":"publisher","DOI":"10.1159\/000056712"},{"key":"e_1_2_10_106_2","first-page":"348","article-title":"Posttransfusion anaphylactic reactions in a patient with severe von Willebrand disease: role of complement and alloantibodies to von Willebrand factor","volume":"125","author":"Bergamaschini L","year":"1995","journal-title":"J Lab Clin Med"},{"issue":"1","key":"e_1_2_10_107_2","article-title":"Successful induction of immune tolerance (IT) in a patient with severe von Willebrand\u2019s disease (VWD) and an inhibitor","volume":"2","author":"Di Michele DM","year":"1996","journal-title":"Haemophilia"},{"key":"e_1_2_10_108_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1987.tb01458.x"},{"issue":"2","key":"e_1_2_10_109_2","article-title":"Combined treatment with intermediate purity factor VIII concentrate and recombinant factor VIII in Type 3 von Willebrand disease and anti\u2010von Willebrand antibodies","volume":"12","author":"Scaraggi FA","year":"2006","journal-title":"Haemophilia"},{"key":"e_1_2_10_110_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra040403"},{"key":"e_1_2_10_111_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-949666"},{"key":"e_1_2_10_112_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00009.x"},{"key":"e_1_2_10_113_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.1988.tb00825.x"},{"key":"e_1_2_10_114_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1989.tb00227.x"},{"key":"e_1_2_10_115_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1987.tb02981.x"},{"key":"e_1_2_10_116_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3025.x"},{"key":"e_1_2_10_117_2","first-page":"753","article-title":"In vitro characterization of various factor VIII concentrates","volume":"37","author":"Yoshioka A","year":"1987","journal-title":"Arzneimittelforsch\/Drug Res"},{"key":"e_1_2_10_118_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V108.11.4076.4076","article-title":"Safety and efficacy of von Willebrand factor\/factor VIII concentrate (Humate\u2010P) for prophylaxis of excessive bleeding during elective surgery in patients with von Willebrand disease","volume":"108","author":"Bernstein J","year":"2006","journal-title":"Blood"},{"key":"e_1_2_10_119_2","doi-asserted-by":"crossref","first-page":"98b","DOI":"10.1182\/blood.V108.11.4077.4077","article-title":"Pharmacokinetic evaluation of von Willebrand factor\/factorVIII concentrate (Humate\u2010P) prior to elective surgery in patients with von Willebrand disease","volume":"108","author":"Di Paola J","year":"2006","journal-title":"Blood"},{"key":"e_1_2_10_120_2","article-title":"von Willebrand Factor \/Factor VIII Concentrate (Humate\u2010P) is safe and effective in the prevention of perioperative bleeding in patients with very low von Willebrand Factor: Ristocetin Cofactor (VWF:RCo)","volume":"108","author":"Gill JC","year":"2006","journal-title":"Blood"},{"key":"e_1_2_10_121_2","unstructured":"GillJC LeissingerC DiPJ BernsteinJ RagniMV ShopnickR et\u00a0al.Von Willebrand factor\/factor VIII concentrate effectively prevents excessive bleeding in patients with very low VWF:RCo plasma levels. XXI Congress of the International Society on Thrombosis and Haemostasis 6\u201312 July Geneva Switzerland 2007(abstract and poster P\u2010S\u2010224)."},{"key":"e_1_2_10_122_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02588.x"},{"key":"e_1_2_10_123_2","article-title":"Dose linerarity of a von Willebrand\/factor VIII concentrate (Haemate P) in elective surgery in von Willebrand disease patients","volume":"102","author":"Mannucci PM","year":"2003","journal-title":"Blood"},{"key":"e_1_2_10_124_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1999.0050s2060.x"},{"key":"e_1_2_10_125_2","first-page":"159","article-title":"H\u00e4mophilie und Hepatitis","volume":"20","author":"Schimpf K","year":"1980","journal-title":"Die gelben Hefte"},{"key":"e_1_2_10_126_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.287.6407.1754"},{"key":"e_1_2_10_127_2","first-page":"3.4","volume-title":"Rationelle Therapie und Diagnose von h\u00e4morrhagischen und thrombophilen Diathesen. Verhandlungsbericht der 29. Tagung der Deutschen Arbeitsgemeinschaft f\u00fcr Blutgerrinungsforschung in Saarbr\u00fccken, February 1985","author":"Schimpf K","year":"1986"},{"key":"e_1_2_10_128_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00321210"},{"key":"e_1_2_10_129_2","first-page":"3.48","volume-title":"Rationelle Therapie und Diagnose von h\u00e4morrhagischen und thrombophilen Diathesen. Verhandlungsbericht der 29. Tagung der Deutschen Arbeitsgemeinschaft f\u00fcr Blutgerrinungsforschung in Saarbr\u00fccken, Februar 1985","author":"Schramm W","year":"1986"},{"key":"e_1_2_10_130_2","first-page":"619","article-title":"[Factor VIII concentrate, highly purified and heated in solution]","volume":"31","author":"Heimburger N","year":"1981","journal-title":"Arzneimittelforschung"},{"key":"e_1_2_10_131_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(88)90561-2"},{"key":"e_1_2_10_132_2","first-page":"621","article-title":"Pasteurization as an efficient method to inactivate blood borne viruses in factor VIII concentrates","volume":"36","author":"Hilfenhaus J","year":"1986","journal-title":"Arzneimittelforsch\/Drug Res"},{"key":"e_1_2_10_133_2","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V106.11.4171.4171","article-title":"Removal of prions by the manufacturing process of Haemate P\/Humate\u2010P","volume":"106","author":"Groener A","year":"2005","journal-title":"Blood"},{"key":"e_1_2_10_134_2","unstructured":"NowakT Sch\u00e4ferW Gr\u00f6nerAAn integrated approach to effective pathogen reduction for a plasma\u2010derived vWF\/FVIII concentrate. XXI Congress of the International Society on Thrombosis and Haemostasis 6\u201312 July Geneva Switzerland 2007(abstract P\u2010M\u2010099)."},{"key":"e_1_2_10_135_2","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1055\/s-0038-1647016","article-title":"Luminography \u2013 an alternative assay for detection of von Willebrand factor multimers","volume":"60","author":"Schneppenheim R","year":"1988","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_136_2","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0308-2261(21)00379-9","article-title":"Von Willebrand\u2019s disease","volume":"12","author":"Zimmerman TS","year":"1983","journal-title":"Clin Haematol"},{"key":"e_1_2_10_137_2","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1182\/blood.V53.6.1095.1095","article-title":"Comparison of factor VIII\u2010related von Willebrand factor proteins prepared from human cryoprecipitate and factor VIII concentrate","volume":"53","author":"Weinstein M","year":"1979","journal-title":"Blood"},{"key":"e_1_2_10_138_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1989.tb02031.x"},{"key":"e_1_2_10_139_2","first-page":"289","article-title":"Plasma product treatment in various types of von Willebrand\u2019s disease","volume":"24","author":"Berntorp E","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_10_140_2","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1182\/blood.V72.3.1100.bloodjournal7231100","article-title":"Humate\u2010P for treatment of von Willebrand disease","volume":"72","author":"Czapek EE","year":"1988","journal-title":"Blood"},{"key":"e_1_2_10_141_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.1998.0040s3033.x"},{"key":"e_1_2_10_142_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00320748"},{"issue":"1","key":"e_1_2_10_143_2","article-title":"Successful treatment of urgent life or limb threatening bleeding or emergent surgery in von Willebrand disease (VWD) with Humate\u2010P (factor VIII\/VWF concentrate)","volume":"94","author":"Goldsmith JC","year":"1999","journal-title":"Blood"},{"key":"e_1_2_10_144_2","first-page":"1654","article-title":"Diagnostik und Therapie des von Willebrand\u2010Syndroms [Diagnostics and therapy of the von Willebrand syndrome]","volume":"38","author":"Hach\u2010Wunderle V","year":"1987","journal-title":"Medwelt"},{"key":"e_1_2_10_145_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00319766"},{"key":"e_1_2_10_146_2","first-page":"304","article-title":"Haemate P in children with von Willebrand\u2019s disease","volume":"24","author":"Kreuz W","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_10_147_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1612977"},{"key":"e_1_2_10_148_2","first-page":"463","volume-title":"Hemophilia and von Willebrand\u2019s Disease in the 1990s","author":"Scharrer I","year":"1991"},{"key":"e_1_2_10_149_2","first-page":"298","article-title":"Experience with Haemate P in von Willebrand\u2019s disease in adults","volume":"24","author":"Scharrer I","year":"1994","journal-title":"Haemostasis"},{"key":"e_1_2_10_150_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-994004"},{"key":"e_1_2_10_151_2","first-page":"353","article-title":"Heat\u2010treated factor VIII\/von Willebrand factor concentrate in platelet\u2010type von Willebrand\u2019s disease","volume":"17","author":"Takahashi H","year":"1987","journal-title":"Haemostasis"},{"key":"e_1_2_10_152_2","first-page":"43","article-title":"Von Willebrands\u2019s disease: a therapeutic challenge","volume":"4","author":"Aledort LM","year":"1991","journal-title":"Biomedical Progress"},{"key":"e_1_2_10_153_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2006-949668"},{"key":"e_1_2_10_154_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V79.12.3130.bloodjournal79123130"},{"issue":"1","key":"e_1_2_10_155_2","article-title":"Comparison of von Willebrand factor activities measured by ristocetin cofactor assay and two different VWF\u2010collagen\u2010binding\u2010assays in VWF\/FVIII\u2010concentrates","volume":"1","author":"Suiter TM","year":"2003","journal-title":"J Thromb Haemost"},{"issue":"1","key":"e_1_2_10_156_2","article-title":"Comparative evaluation of high\u2010molecular\u2010weight von Willebrand factor multimers and their impact on VWF\u2010activity in different VWF\/FVIII\u2010concentrates","volume":"82","author":"Walter O","year":"2003","journal-title":"Ann Hematol"},{"key":"e_1_2_10_157_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01836069"},{"key":"e_1_2_10_158_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1992.tb01198.x"},{"key":"e_1_2_10_159_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00816.x"},{"key":"e_1_2_10_160_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1351-8216.2003.00809.x"},{"key":"e_1_2_10_161_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V99.2.450"},{"key":"e_1_2_10_162_2","first-page":"173","article-title":"The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease","volume":"71","author":"Hanna WT","year":"1994","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_163_2","doi-asserted-by":"publisher","DOI":"10.1016\/0049-3848(92)90109-N"},{"key":"e_1_2_10_164_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198704093161505"},{"key":"e_1_2_10_165_2","first-page":"513","article-title":"Report on the efficacy of Haemate P in Canadian von Willebrand disease (vWd) patients","author":"Blanchette V","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_166_2","article-title":"Haemate P dosing trends among 97 Canadian von Willebrand disease (vWd) patients","author":"Pai M","year":"1997","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_167_2","article-title":"Continuous infusion of factor VIII after elective surgery in children with haemophilia A and von Willebrand disease","volume":"73","author":"Auerswald G","year":"1995","journal-title":"Thromb Haemost"},{"issue":"1","key":"e_1_2_10_168_2","article-title":"Continuous infusion of factor VIII after elective surgery in children with haemophilia A and von Willebrand disease","volume":"2","author":"Auerswald G","year":"1996","journal-title":"Haemophilia"},{"key":"e_1_2_10_169_2","first-page":"191","article-title":"Kontinuierliche Infusion von Faktoren\u2010Konzentraten nach Operation bei Kindern mit H\u00e4mophilie","volume":"37","author":"Auerswald G","year":"1997","journal-title":"Die gelben Hefte"},{"key":"e_1_2_10_170_2","first-page":"1279","article-title":"Efficacy and safety of factor VIII\/von Willebrand\u2019s factor concentrate (Haemate\u2010P) in preventing bleeding during surgery or invasive procedures in patients with von Willebrand disease","volume":"88","author":"Franchini M","year":"2003","journal-title":"Haematologica"},{"key":"e_1_2_10_171_2","first-page":"366","article-title":"[Prevalence, pathophysiology, diagnosis and treatment of von Willebrand syndrome in orthopedic trauma patients]","volume":"28","author":"Kurth AA","year":"1999","journal-title":"Orthopaede"},{"key":"e_1_2_10_172_2","first-page":"18","article-title":"Surgery in von Willebrand disease patients","volume":"15","author":"Scharrer I","year":"2002","journal-title":"Biomed Progr"},{"key":"e_1_2_10_173_2","doi-asserted-by":"publisher","DOI":"10.1097\/00001721-200406000-00006"},{"issue":"2","key":"e_1_2_10_174_2","article-title":"Multicenter retrospective survey on efficacy and safety of Haemate P in a large cohort of Italian patients with von Willebrand disease","volume":"12","author":"Federici AB","year":"2006","journal-title":"Haemophilia"},{"key":"e_1_2_10_175_2","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.11124"},{"key":"e_1_2_10_176_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2005.01132.x"},{"key":"e_1_2_10_177_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00893.x"},{"key":"e_1_2_10_178_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1642511"},{"key":"e_1_2_10_179_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)90166-3"},{"key":"e_1_2_10_180_2","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/15.10.1711"},{"key":"e_1_2_10_181_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-11-4188"},{"key":"e_1_2_10_182_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613227"},{"key":"e_1_2_10_183_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0037-1613225"},{"key":"e_1_2_10_184_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198910263211702"},{"key":"e_1_2_10_185_2","article-title":"No HIV\u20101 and HIV\u20102 infection in children with hemophilia and von Willebrand disease treated with pasteurized factor VIII products since 1979\/80","volume":"59","author":"Kreuz WD","year":"1989","journal-title":"Blut"},{"key":"e_1_2_10_186_2","article-title":"Eleven years of virus safety (HCV, PARVO B19, HBV, HIV) with pasteurized clotting factor concentrates","volume":"62","author":"Kreuz W","year":"1991","journal-title":"Ann Hematol"},{"key":"e_1_2_10_187_2","doi-asserted-by":"crossref","unstructured":"KreuzW AuerswaldG RoggendorfM SchwarzT FunkM LindeR et\u00a0al.Anti\u2010HCV and anti\u2010B 19 Pr\u00e4valenz nach Substitution mit pasteurisierten Gerinnungspr\u00e4paraten bei bisher unbehandelten Patienten. 21. H\u00e4mophilie\u2010Symposion Hamburg 1990:Springer\u2010Verlag 1991;164\u20139.","DOI":"10.1007\/978-3-642-76764-7_34"},{"key":"e_1_2_10_188_2","article-title":"Virus safety of pasteurized clotting factor concentrates \u2013 an eleven year follow up","volume":"65","author":"Kreuz W","year":"1991","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_189_2","doi-asserted-by":"crossref","unstructured":"KreuzW KlarmannD AuerswaldG EhrenforthS LindeR MentzerD et\u00a0al.Pr\u00e4valenz von Anti\u2010Hepatitis A und Anti\u2010Parvo B 19 bei Kindern mit Blutgerinnungsst\u00f6rungen. 23 H\u00e4mophilie\u2010Symposion Hamburg 1992:Springer\u2010Verlag 1993;48.","DOI":"10.1007\/978-3-642-78359-3_31"},{"key":"e_1_2_10_190_2","doi-asserted-by":"crossref","unstructured":"KreuzW KlarmannD AuerswaldG EhrenforthS LindeR MentzerD et\u00a0al.Anti\u2010HCV Pr\u00e4valenz bei Kindern mit Blutgerinnungsst\u00f6rungen \u2010 Untersuchungsergebnisse mit dem Test der 1. und 2. Generation. 23. H\u00e4mophilie\u2010Symposion Hamburg 1992:Springer\u2010Verlag 1993;56.","DOI":"10.1007\/978-3-642-78359-3_34"},{"key":"e_1_2_10_191_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(93)93050-B"},{"issue":"1","key":"e_1_2_10_192_2","article-title":"Anti\u2010HCV Prevalence in children with haemophilia and other coagulation disorders \u2013 results of the first and second generation test","volume":"66","author":"Kreuz W","year":"1993","journal-title":"Ann Hematol"},{"issue":"1","key":"e_1_2_10_193_2","article-title":"Prevalence of anti\u2010hepatitis A and Anti\u2010Parvo B19 in children with haemophilia and other coagulation disorders","volume":"66","author":"Kreuz W","year":"1993","journal-title":"Ann Hematol"},{"key":"e_1_2_10_194_2","doi-asserted-by":"crossref","unstructured":"KreuzW KlarmannD AuerswaldG EhrenforthS LindeP MentzerD et\u00a0al.Pr\u00e4valenz von Anti\u2010Hepatitis A und Anti\u2010Parvo B 19 bei Kindern mit Blutgerinnungsst\u00f6rungen. 23. H\u00e4mophilie\u2010Symposion Hamburg 1992:Springer\u2010Verlag 1993;210\u20133.","DOI":"10.1007\/978-3-642-78359-3_31"},{"key":"e_1_2_10_195_2","unstructured":"KreuzW KlarmannD AuerswaldG AubergerK ZiegerB SutorAH et\u00a0al.Absence of Hepatitis A after treatment with pasteurised factor VIII concentrates in children with coagulation disorders. XXI International Congress of the World Federation of Hemophilia 24\u201329 April Mexico City Mexico 1994(abstract 256)."},{"key":"e_1_2_10_196_2","first-page":"503","article-title":"The natural history of hepatitis C virus infection in Italian patients with von Willebrand\u2019s disease: a cohort study","volume":"91","author":"Federici AB","year":"2006","journal-title":"Haematologica"},{"key":"e_1_2_10_197_2","article-title":"Prion removal in the production of coagulation factor concentrate Humate\u2010P from Human Plasma","volume":"98","author":"Vey M","year":"2001","journal-title":"Blood"},{"key":"e_1_2_10_198_2","unstructured":"Sch\u00e4ferW GnauO Seyfert\u2010BrandtW WiegandT VeyM GroschupM et\u00a0al.Removal of prions by the manufacturing process of the VWF\/FVIII coagulation concentrate Haemate P\/Humate\u2010P. XXVII International Congress of the World Federation of Hemophilia 21\u201325 May Vancouver Canada 2006(poster 042)."},{"key":"e_1_2_10_199_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.1996.tb00022.x"},{"key":"e_1_2_10_200_2","unstructured":"KreuzW ScharrerIElimination of Factor VIII inhibitors in 6 children with severe hemophilia A. XVI International Congress of the World Federation of Hemophilia 24\u201328 August Rio de Janeiro Brazil 1984(abstract 178)."},{"key":"e_1_2_10_201_2","unstructured":"KreuzW ScharrerIElimination der Faktor VIII\u2010Hemmk\u00f6rper bei 7 Kindern mit schwerer H\u00e4mophilie A.29. Jahrestagung der Deutschen Arbeitsgemeinschaft f\u00fcr Blutgerrinungsforschung in Saarbr\u00fccken February1985; Saarbrucken Germany:79\u201383(presentation 1.3.3)."},{"key":"e_1_2_10_202_2","article-title":"Elimination of factor VIII inhibitors in children by induction of immune tolerance \u2010 10\u2003years of experience","volume":"59","author":"Kreuz WD","year":"1989","journal-title":"Blut"},{"key":"e_1_2_10_203_2","unstructured":"KreuzW EhrenforthS AuerswaldG LindeR BeegT MentzerD et\u00a0al.Factor VIII inhibitors in haemophilia A; the importance of early and continuous administration of high\u2010dose factor VIII and APCC for the successful treatment and induction of immunotolerance. XX International Congress of the World Federation of Hemophilia 12\u201317 October Athens Greece 1992(abstract 356)."},{"key":"e_1_2_10_204_2","article-title":"Successful immune tolerance therapy of FVIII\u2010inhibitor in children after changing from high to intermediate purity FVIII concentrate","volume":"72","author":"Kreuz W","year":"1996","journal-title":"Ann Hematol"},{"key":"e_1_2_10_205_2","article-title":"Successful immunetolerance therapy of FVIII\u2010Inhibitor in children after changing from high to intermediate purity FVIII concentrate","volume":"2","author":"Kreuz W","year":"1996","journal-title":"Haemophilia"},{"key":"e_1_2_10_206_2","article-title":"Immune tolerance therapy in patients with hemophilia A and inhibitors using pd FVIII concentrates with high content of VWF","volume":"79","author":"Kreuz W","year":"2000","journal-title":"Ann Hematol"},{"key":"e_1_2_10_207_2","doi-asserted-by":"crossref","unstructured":"MentzerD KreuzW AuerswaldGErfolgreiche Faktor VIII\u2010Hemmk\u00f6rperelimination nach Wechsel von \u2018high\u2019\u2010 zu \u2018intermediate\u2019\u2010purity Faktor\u2010VIII\u2010Konzentrat bei Kindern mit H\u00e4mophilie A. 27. H\u00e4mophilie\u2010Symposion Hamburg 1996:Springer\u2010Verlag 1998;187\u201394.","DOI":"10.1007\/978-3-642-80403-8_25"},{"issue":"2","key":"e_1_2_10_208_2","article-title":"High dose of an intermediate purity factor VIII concentrate for induction of immune tolerance in severe haemophilia A with factor VIII inhibitor","volume":"12","author":"Scaraggi FA","year":"2006","journal-title":"Haemophilia"},{"key":"e_1_2_10_209_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(92)90206-Q"},{"key":"e_1_2_10_210_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2516.2000.00366.x"},{"key":"e_1_2_10_211_2","article-title":"Prevalence of hepatitis and HIV in a Group of haemophiliacs","volume":"68","author":"Pollmann H","year":"1994","journal-title":"Ann Hematol"},{"issue":"1","key":"e_1_2_10_212_2","article-title":"15\u2003years experience with virus safety of pasteurised factor VIII concentrates in Germany","volume":"2","author":"Pollmann H","year":"1996","journal-title":"Haemophilia"},{"key":"e_1_2_10_213_2","article-title":"Treatment of hemophiliac children with Haemate HS Behringwerke, a 10\u2003years study on viral safety","volume":"62","author":"K\u00f6hler\u2010Vajta K","year":"1989","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_214_2","article-title":"15\u2003years experience on viral safety of a pasteurized factor VIII concentrate in pediatric patients and young adults","volume":"73","author":"K\u00f6hler\u2010Vajta K","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_215_2","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1055\/s-0038-1653858","article-title":"Hepatitis C and pasteurised factor VIII and IX concentrates","volume":"73","author":"Klarmann D","year":"1995","journal-title":"Thromb Haemost"},{"key":"e_1_2_10_216_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-30197"},{"key":"e_1_2_10_217_2","doi-asserted-by":"publisher","DOI":"10.1016\/0140-6736(92)92393-T"},{"key":"e_1_2_10_218_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2516.2004.00979.x"},{"key":"e_1_2_10_219_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(05)81921-3"},{"key":"e_1_2_10_220_2","first-page":"224","article-title":"Prediction of blood volume in normal human adults","volume":"51","author":"Nadler SB","year":"1962","journal-title":"Surgery"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-0609.2008.01049.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1600-0609.2008.01049.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T09:21:44Z","timestamp":1694683304000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1600-0609.2008.01049.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":219,"journal-issue":{"issue":"s70","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1111\/j.1600-0609.2008.01049.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-0609.2008.01049.x","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,4]]}}}